Klotho Therapeutics, Inc. Information

Helping people live well longer. Klotho Therapeutics, Inc., (KTI) is a privately held biotechnology company developing modified recombinant versions of the human protein Klotho that has shown great potential to delay diseases of aging and improve longevity. Klotho Team has 250+ Years Pharma Experience, 500+ Clinical Trials, including 60+ drug Approvals including numerous Blockbuster Drugs The company builds upon the $200+ million previously invested in Klotho research that demonstrates how Klotho, a naturally occurring protein in humans and animals, can positively impact aging, cognition, kidney function, fibrosis, and cancer. KTI has worldwide patents on Klotho proteins. KTI is well positioned to enter human trials within 12 months focused on its first indication: to slow the progression of kidney failure, which affects up to 40 million patients in the US per year, with over 600,000 currently on dialysis. Kidney disease represents a multi-billion-dollar market opportunity in the U.S. alone.